Concomitant Medications in Patients with Metastatic Urothelial Carcinoma Receiving Enfortumab Vedotin: Real-world Data from the ARON-2 Study

Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. Data from 436 patients enrolled in the ARON-2 retrospective study were analyzed according to the concomitant medications used at baseline. Finally, the patients were stratified into three risk groups according to the concomitant drug score based on ATBs, corticosteroids and PPIs. Statistical analysis involved Fisher exact test, Kaplan-Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Inferior survival outcomes were observed in ATB users compared to non-users (OS: 7.3 months, 95%CI 5.0 - 12.3 vs 13.7 months, 95%CI 12.2 - 47.3, p = 0.001; PFS: 5.1 months 95%CI 3.3 - 17.7 vs 8.3 months, 95%CI 7.1 - 47.3, p = 0.001) and also in corticosteroid users compared to non-users (OS: 8.4 months, 95%CI 6.6 - 10.0 vs 14.2 months, 95%CI 12.7 - 47.3, p < 0.001; PFS: 6.0 months 95%CI 4.6 - 7.9 vs 8.9 months, 95%CI 7.2 - 47.3, p = 0.004). In the Cox multivariate analysis, the concomitant drug score was a significant factor predicting both OS (HR = 1.32 [95% CI 1.03 - 1.68], p = 0.026) and PFS (HR = 1.23 [95% CI 1.01 - 1.51], p = 0.044). Our findings suggest detrimental impact of concomitant use of ATBs and corticosteroids on survival outcomes and the prognostic utility of the concomitant drug score in previously treated mUC patients receiving EV.

References

Tomisaki I, Harada M, Minato A, Nagata Y, Kimuro R, Higashijima K . Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma. Anticancer Res. 2022; 42(3):1629-1634. DOI: 10.21873/anticanres.15638. View

Becattini S, Taur Y, Pamer E . Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol Med. 2016; 22(6):458-478. PMC: 4885777. DOI: 10.1016/j.molmed.2016.04.003. View

Powles T, Rosenberg J, Sonpavde G, Loriot Y, Duran I, Lee J . Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 384(12):1125-1135. PMC: 8450892. DOI: 10.1056/NEJMoa2035807. View

Gopalakrishnan V, Helmink B, Spencer C, Reuben A, Wargo J . The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 2018; 33(4):570-580. PMC: 6529202. DOI: 10.1016/j.ccell.2018.03.015. View

Domb C, Garcia J, Barata P, Mendiratta P, Rao S, Brown J . Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. Ther Adv Urol. 2024; 16:17562872241249073. PMC: 11110528. DOI: 10.1177/17562872241249073. View

Kraynov E, Kamath A, Walles M, Tarcsa E, Deslandes A, Iyer R . Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. Drug Metab Dispos. 2015; 44(5):617-23. DOI: 10.1124/dmd.115.068049. View

Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T . Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. Urol Oncol. 2022; 40(7):346.e1-346.e8. DOI: 10.1016/j.urolonc.2022.02.020. View

Chan K, Oza A, Siu L . The statins as anticancer agents. Clin Cancer Res. 2003; 9(1):10-9. View

Pinato D, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T . Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. 2019; 5(12):1774-1778. PMC: 6743060. DOI: 10.1001/jamaoncol.2019.2785. View

10.

Maslov D, Tawagi K, Kc M, Simenson V, Yuan H, Parent C . Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. 2021; 9(7). PMC: 8258666. DOI: 10.1136/jitc-2020-002261. View

11.

Clooney A, Bernstein C, Leslie W, Vagianos K, Sargent M, Laserna-Mendieta E . A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016; 43(9):974-84. DOI: 10.1111/apt.13568. View

12.

Jernberg C, Lofmark S, Edlund C, Jansson J . Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007; 1(1):56-66. DOI: 10.1038/ismej.2007.3. View

13.

Takada K, Buti S, Bersanelli M, Shimokawa M, Takamori S, Matsubara T . Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. Eur J Cancer. 2022; 172:199-208. DOI: 10.1016/j.ejca.2022.06.002. View

14.

Reddy M, Kader K . Follow-up Management of Cystectomy Patients. Urol Clin North Am. 2018; 45(2):241-247. DOI: 10.1016/j.ucl.2018.01.001. View

15.

Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M . Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One. 2014; 9(3):e93132. PMC: 3965531. DOI: 10.1371/journal.pone.0093132. View

16.

Haimerl L, Strobach D, Mannell H, Stief C, Buchner A, Karl A . Retrospective evaluation of the impact of non-oncologic chronic drug therapy on the survival in patients with bladder cancer. Int J Clin Pharm. 2021; 44(2):339-347. PMC: 9007758. DOI: 10.1007/s11096-021-01343-x. View

17.

Bruera S, Suarez-Almazor M . The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022; 12:928390. PMC: 9445222. DOI: 10.3389/fonc.2022.928390. View

18.

Hopkins A, Kichenadasse G, Karapetis C, Rowland A, Sorich M . Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol. 2020; 78(4):540-543. DOI: 10.1016/j.eururo.2020.06.061. View

19.

Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R . Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021; 150:224-231. DOI: 10.1016/j.ejca.2021.03.041. View

20.

Wu T, Yang L, Jiang J, Ni Y, Zhu J, Zheng X . Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci. 2017; 192:173-182. DOI: 10.1016/j.lfs.2017.11.049. View